http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 03:34:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/Barclays+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Equalweight/26821072.html <p>Barclays analyst Etzer Darout downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Overweight to Equalweight with a price target of $77.00 (from $74.00).</p><p>The analyst comments: “We are downgrading FBRX to Equal Weight and see limited risk of a competing bid emerging, with no obvious upcoming clinical catalysts that are likely to disrupt the expected 3Q26 deal close timeline outlined in the announcement. In our view, the acquisition is particularly notable because it represents the first transaction involving an anti‑CD122 therapy and, in our view, provides further validation of the IL‑2/IL‑15 signaling pathway. The transaction follows FBRX’s recent positive Phase 1b data http://www.streetinsider.com/Downgrades/Barclays+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Equalweight/26821072.html Tue, 28 Jul 2026 03:34:28 -0400 FBRX http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Equalweight/26821072.html <p>Barclays analyst Etzer Darout downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Overweight to Equalweight with a price target of $77.00 (from $74.00).</p><p>The analyst comments: “We are downgrading FBRX to Equal Weight and see limited risk of a competing bid emerging, with no obvious upcoming clinical catalysts that are likely to disrupt the expected 3Q26 deal close timeline outlined in the announcement. In our view, the acquisition is particularly notable because it represents the first transaction involving an anti‑CD122 therapy and, in our view, provides further validation of the IL‑2/IL‑15 signaling pathway. The transaction follows FBRX’s recent positive Phase 1b data http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Equalweight/26821072.html Tue, 28 Jul 2026 03:34:28 -0400 FBRX http://www.streetinsider.com/Downgrades/Brookline+Capital+Markets+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26817905.html <p>Brookline Capital Markets analyst Kumaraguru Raja downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Buy to Hold with a price target of $77.00.</p><p>For an analyst ratings summary and ratings history on Forte Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=FBRX">click here</a>. For more ratings news on Forte Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FBRX&amp;type=analyst">click here</a>.</p><p>Shares of Forte Biosciences Inc. closed at $54.78 yesterday.</p> http://www.streetinsider.com/Downgrades/Brookline+Capital+Markets+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26817905.html Mon, 27 Jul 2026 11:30:04 -0400 FBRX http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+In+Line/26817896.html <p>Evercore ISI analyst Gavin Clark-Gartner downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Outperform to In Line with a price target of $77.00.</p><p>For an analyst ratings summary and ratings history on Forte Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=FBRX">click here</a>. For more ratings news on Forte Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FBRX&amp;type=analyst">click here</a>.</p><p>Shares of Forte Biosciences Inc. closed at $54.78 yesterday.</p> http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+In+Line/26817896.html Mon, 27 Jul 2026 11:29:51 -0400 FBRX http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html <p>TD Cowen analyst Yaron Werber downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Buy to Hold with a price target of $77.00.</p><p>The analyst comments "We are downgrading FBRX shares to Hold as ARGX has agreed to acquire the company. FBRX’s FB102 is a first-in-class anti-CD122 mAb with clinical PoC in vitiligo and celiac disease that fits well into argenx’s immunology-focused portfolio and adds a differentiated approach to targeting pathogenic T-cell/NK-cell biology. Deal should close in Q3:26."</p><p>For an analyst ratings summary and ratings history on Forte Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=FBRX">click here</a>. For more ratings news on Forte Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FBRX&amp;type=analyst">click here</a>.</p><p>Shares http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html Mon, 27 Jul 2026 08:14:14 -0400 ARGX FBRX http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html <p>TD Cowen analyst Yaron Werber downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Buy to Hold with a price target of $77.00.</p><p>The analyst comments "We are downgrading FBRX shares to Hold as ARGX has agreed to acquire the company. FBRX’s FB102 is a first-in-class anti-CD122 mAb with clinical PoC in vitiligo and celiac disease that fits well into argenx’s immunology-focused portfolio and adds a differentiated approach to targeting pathogenic T-cell/NK-cell biology. Deal should close in Q3:26."</p><p>For an analyst ratings summary and ratings history on Forte Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=FBRX">click here</a>. For more ratings news on Forte Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FBRX&amp;type=analyst">click here</a>.</p><p>Shares http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html Mon, 27 Jul 2026 08:14:14 -0400 ARGX FBRX http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html <p>TD Cowen analyst Yaron Werber downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Buy to Hold with a price target of $77.00.</p><p>The analyst comments "We are downgrading FBRX shares to Hold as ARGX has agreed to acquire the company. FBRX’s FB102 is a first-in-class anti-CD122 mAb with clinical PoC in vitiligo and celiac disease that fits well into argenx’s immunology-focused portfolio and adds a differentiated approach to targeting pathogenic T-cell/NK-cell biology. Deal should close in Q3:26."</p><p>For an analyst ratings summary and ratings history on Forte Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=FBRX">click here</a>. For more ratings news on Forte Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FBRX&amp;type=analyst">click here</a>.</p><p>Shares http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html Mon, 27 Jul 2026 08:14:14 -0400 ARGX FBRX http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html <p>TD Cowen analyst Yaron Werber downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Buy to Hold with a price target of $77.00.</p><p>The analyst comments "We are downgrading FBRX shares to Hold as ARGX has agreed to acquire the company. FBRX’s FB102 is a first-in-class anti-CD122 mAb with clinical PoC in vitiligo and celiac disease that fits well into argenx’s immunology-focused portfolio and adds a differentiated approach to targeting pathogenic T-cell/NK-cell biology. Deal should close in Q3:26."</p><p>For an analyst ratings summary and ratings history on Forte Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=FBRX">click here</a>. For more ratings news on Forte Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FBRX&amp;type=analyst">click here</a>.</p><p>Shares http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Downgrades+Forte+Biosciences+Inc.+%28FBRX%29+to+Hold/26816491.html Mon, 27 Jul 2026 08:14:14 -0400 ARGX FBRX http://www.streetinsider.com/Mergers+and+Acquisitions/argenx+to+acquire+Forte+Biosciences+for+%242.2+billion/26814937.html <p>argenx (Euronext & Nasdaq: ARGX) has agreed to acquire Forte Biosciences, Inc. (Nasdaq: FBRX) through a cash tender offer of $77 per share, representing a total equity value of approximately $2.2 billion, according to a press release from the companies.</p> <p>The offer price represents a premium of approximately 86% to Forte Biosciences' volume-weighted average price since the company reported positive Phase 1b data in vitiligo on July 9, 2026. The transaction will be funded entirely from cash on hand and is not subject to a financing condition.</p> <p>The acquisition centers on FB102, Forte Biosciences' lead anti-CD122 antibody, which has shown clinical proof-of-concept http://www.streetinsider.com/Mergers+and+Acquisitions/argenx+to+acquire+Forte+Biosciences+for+%242.2+billion/26814937.html Mon, 27 Jul 2026 01:00:15 -0400 FBRX http://www.streetinsider.com/Press+Releases/argenx+to+Acquire+Forte+Biosciences%2C+Inc.%2C+Adding+First-in-Class+anti-CD122+Antibody%2C+FB102%2C+to+its+Immunology+Pipeline/26814935.html <p align="center"><br /></p> <ul type="disc"><li style="margin-bottom:8pt;"><i>Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth</i></li><li style="margin-bottom:8pt;"><i>FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation</i></li><li style="margin-bottom:8pt;"><i>Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology</i></li><li style="margin-bottom:8pt;"><i>argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction</i></li></ul> <p align="justify"><b>July 27, 2026 http://www.streetinsider.com/Press+Releases/argenx+to+Acquire+Forte+Biosciences%2C+Inc.%2C+Adding+First-in-Class+anti-CD122+Antibody%2C+FB102%2C+to+its+Immunology+Pipeline/26814935.html Mon, 27 Jul 2026 01:00:00 -0400 FBRX http://www.streetinsider.com/Globe+Newswire/argenx+to+Acquire+Forte+Biosciences%2C+Inc.%2C+Adding+First-in-Class+anti-CD122+Antibody%2C+FB102%2C+to+its+Immunology+Pipeline/26814935.html <p align="center"><br /></p> <ul type="disc"><li style="margin-bottom:8pt;"><i>Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth</i></li><li style="margin-bottom:8pt;"><i>FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation</i></li><li style="margin-bottom:8pt;"><i>Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology</i></li><li style="margin-bottom:8pt;"><i>argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction</i></li></ul> <p align="justify"><b>July 27, 2026 http://www.streetinsider.com/Globe+Newswire/argenx+to+Acquire+Forte+Biosciences%2C+Inc.%2C+Adding+First-in-Class+anti-CD122+Antibody%2C+FB102%2C+to+its+Immunology+Pipeline/26814935.html Mon, 27 Jul 2026 01:00:00 -0400 FBRX http://www.streetinsider.com/New+Coverage/Barclays+Starts+Forte+Biosciences+Inc.+%28FBRX%29+at+Overweight/26791067.html <p>Barclays analyst Etzer Darout initiates coverage on Forte Biosciences Inc. (NASDAQ: FBRX) with a Overweight rating and a price target of $74.00.</p><p>The analyst comments: “Our Overweight rating is driven by the upside optionality in FB102 across immunological disorders based on the data generated to date in celiac disease (CeD) and vitiligo. Despite the evolving competitive dynamics in FB102's lead indication (CeD), where there are currently no approved biologics, even conservative sales assumptions provide upside to our valuation. We view FB102 development in vitiligo as an additional source of upside, and potentially more compelling mechanistically given our view on the biological http://www.streetinsider.com/New+Coverage/Barclays+Starts+Forte+Biosciences+Inc.+%28FBRX%29+at+Overweight/26791067.html Tue, 21 Jul 2026 03:47:44 -0400 FBRX http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Forte+Biosciences+Inc.+%28FBRX%29+at+Overweight/26791067.html <p>Barclays analyst Etzer Darout initiates coverage on Forte Biosciences Inc. (NASDAQ: FBRX) with a Overweight rating and a price target of $74.00.</p><p>The analyst comments: “Our Overweight rating is driven by the upside optionality in FB102 across immunological disorders based on the data generated to date in celiac disease (CeD) and vitiligo. Despite the evolving competitive dynamics in FB102's lead indication (CeD), where there are currently no approved biologics, even conservative sales assumptions provide upside to our valuation. We view FB102 development in vitiligo as an additional source of upside, and potentially more compelling mechanistically given our view on the biological http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Forte+Biosciences+Inc.+%28FBRX%29+at+Overweight/26791067.html Tue, 21 Jul 2026 03:47:44 -0400 FBRX http://www.streetinsider.com/Investing/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html <p>Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares. </p> <p>By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&amp;P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.</p> <p>Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Enovix surged 17% after the battery technology company appointed former Apple executive http://www.streetinsider.com/Investing/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html Thu, 09 Jul 2026 08:39:56 -0400 FBRX PEP RXT http://www.streetinsider.com/Investing/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html <p>Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares. </p> <p>By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&amp;P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.</p> <p>Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Enovix surged 17% after the battery technology company appointed former Apple executive http://www.streetinsider.com/Investing/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html Thu, 09 Jul 2026 08:39:56 -0400 FBRX PEP RXT http://www.streetinsider.com/Investing/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html <p>Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares. </p> <p>By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&amp;P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.</p> <p>Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Enovix surged 17% after the battery technology company appointed former Apple executive http://www.streetinsider.com/Investing/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html Thu, 09 Jul 2026 08:39:56 -0400 FBRX PEP RXT http://www.streetinsider.com/General+News/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html <p>Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares. </p> <p>By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&amp;P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.</p> <p>Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Enovix surged 17% after the battery technology company appointed former Apple executive http://www.streetinsider.com/General+News/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html Thu, 09 Jul 2026 08:39:56 -0400 FBRX PEP RXT http://www.streetinsider.com/General+News/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html <p>Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares. </p> <p>By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&amp;P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.</p> <p>Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Enovix surged 17% after the battery technology company appointed former Apple executive http://www.streetinsider.com/General+News/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html Thu, 09 Jul 2026 08:39:56 -0400 FBRX PEP RXT http://www.streetinsider.com/General+News/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html <p>Investing.com - U.S. stock index futures were mixed on Thursday as investors weighed escalating tensions between the United States and Iran against a continued rebound in semiconductor shares. </p> <p>By 07:09 ET (11:09 GMT), the Dow futures contract had slipped by 85 points, or 0.2%, S&amp;P 500 futures had gained 12 points, or 0.2%, and Nasdaq 100 futures had advanced by 176 points, or 0.6%.</p> <p>Technology and healthcare stocks led premarket gains, while investors also reacted to earnings and strategic partnership announcements.</p> <p>Here are some of the biggest premarket U.S. stock movers today:</p> <p>Enovix surged 17% after the battery technology company appointed former Apple executive http://www.streetinsider.com/General+News/Enovix%2C+Forte+Biosciences+rally+premarket%3B+PepsiCo+slips/26750778.html Thu, 09 Jul 2026 08:39:56 -0400 FBRX PEP RXT http://www.streetinsider.com/Corporate+News/Forte+Biosciences+FB102+shows+vitiligo+improvement+in+phase+1b+trial/26750479.html <p>Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive results from a double-blind, placebo-controlled phase 1b study of FB102 in vitiligo, according to a company statement.</p><p>The trial enrolled 43 subjects randomized 3:1, with 32 receiving FB102 and 11 receiving placebo. In the protocol-defined efficacy-evaluable population, FB102 achieved a 29.6% mean improvement from baseline in the Facial Vitiligo Area Scoring Index (FVASI) at week 24, compared to 7.9% for placebo, a placebo-adjusted benefit of 21.7% (p=0.020). Statistically significant improvement was observed as early as day 64 (p=0.023).</p><p>In subjects with greater disease involvement, defined as baseline FVASI of at least 0.75, FB102 achieved a http://www.streetinsider.com/Corporate+News/Forte+Biosciences+FB102+shows+vitiligo+improvement+in+phase+1b+trial/26750479.html Thu, 09 Jul 2026 08:02:46 -0400 FBRX http://www.streetinsider.com/FDA/Forte+Biosciences+FB102+shows+vitiligo+improvement+in+phase+1b+trial/26750479.html <p>Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive results from a double-blind, placebo-controlled phase 1b study of FB102 in vitiligo, according to a company statement.</p><p>The trial enrolled 43 subjects randomized 3:1, with 32 receiving FB102 and 11 receiving placebo. In the protocol-defined efficacy-evaluable population, FB102 achieved a 29.6% mean improvement from baseline in the Facial Vitiligo Area Scoring Index (FVASI) at week 24, compared to 7.9% for placebo, a placebo-adjusted benefit of 21.7% (p=0.020). Statistically significant improvement was observed as early as day 64 (p=0.023).</p><p>In subjects with greater disease involvement, defined as baseline FVASI of at least 0.75, FB102 achieved a http://www.streetinsider.com/FDA/Forte+Biosciences+FB102+shows+vitiligo+improvement+in+phase+1b+trial/26750479.html Thu, 09 Jul 2026 08:02:46 -0400 FBRX http://www.streetinsider.com/Press+Releases/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html <p class="bwalignc"> <i>Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24</i> </p><p class="bwalignc"> <i>FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells</i> </p><p class="bwalignc"> <i>Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET</i> </p> <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54567379&amp;newsitemid=20260709892301&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=60561b7050c7b22a674519b3c3ca9497" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: </p><ul class="bwlistdisc"> <li> FB102 achieved http://www.streetinsider.com/Press+Releases/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html Thu, 09 Jul 2026 08:00:00 -0400 FBRX O.21049479 http://www.streetinsider.com/Press+Releases/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html <p class="bwalignc"> <i>Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24</i> </p><p class="bwalignc"> <i>FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells</i> </p><p class="bwalignc"> <i>Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET</i> </p> <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54567379&amp;newsitemid=20260709892301&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=60561b7050c7b22a674519b3c3ca9497" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: </p><ul class="bwlistdisc"> <li> FB102 achieved http://www.streetinsider.com/Press+Releases/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html Thu, 09 Jul 2026 08:00:00 -0400 FBRX O.21049479 http://www.streetinsider.com/Business+Wire/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html <p class="bwalignc"> <i>Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24</i> </p><p class="bwalignc"> <i>FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells</i> </p><p class="bwalignc"> <i>Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET</i> </p> <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54567379&amp;newsitemid=20260709892301&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=60561b7050c7b22a674519b3c3ca9497" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: </p><ul class="bwlistdisc"> <li> FB102 achieved http://www.streetinsider.com/Business+Wire/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html Thu, 09 Jul 2026 08:00:00 -0400 FBRX O.21049479 http://www.streetinsider.com/Business+Wire/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html <p class="bwalignc"> <i>Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24</i> </p><p class="bwalignc"> <i>FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells</i> </p><p class="bwalignc"> <i>Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET</i> </p> <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54567379&amp;newsitemid=20260709892301&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=60561b7050c7b22a674519b3c3ca9497" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: </p><ul class="bwlistdisc"> <li> FB102 achieved http://www.streetinsider.com/Business+Wire/FB102+Achieves+Statistically+Significant+Improvement+in+Vitiligo+at+Week+24+After+Completion+of+12-Week+Treatment+Period/26750367.html Thu, 09 Jul 2026 08:00:00 -0400 FBRX O.21049479